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InTROduCTIOn
Fabry disease (a-galactosidase A deficiency) is an inherited 
lysosomal storage disorder, characterized by the accumulation 
of glycosphingolipids, mainly globotriaosylceramide (GL-3) 
virtually in all tissues and organs. DNA region encoding a-
galactosidase is localized on chromosome X, locus q 22.11. 
Males are mainly affected, but heterozygotic females can also 
be mildly symptomatic [1]. One case of a homozygotic female 
was described with severe symptoms of Fabry disease occur-
ring at the age of 8 years [2]. In males initial clinical symp-
toms of the disease usually appear at school age and include: 
severe acroparaesthesia of upper and lower limbs, hypohidrosis 
and disturbances in thermoregulation. They might be joined 
some years later by angiokeratoma formation localized on the 
skin of hip, perineum and thighs, hypoacusis and gastro-intes-
tinal symptoms (nausea, diarrhea and stomach pain). Progres-
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sive accumulation of glycosphingolipids in kidneys leads to the 
destruction of glomeruli (approx. at 30 years of age) and in the 
next decades to the development of end-stage renal failure [3]. 
Phenotype of the disease may vary. In some patients it may 
take a form limited to the heart and presenting mainly as a 
hypertrophic cardiomyopathy; especially frequent in heterozy-
gotic women [3]. In others the disease may be limited to the 
isolated limbs acroparaesthesia [1,3]. For years only symptom-
atic treatment of Fabry disease was available. Life expectancy 
of such treated patients was decreased to about 40–50 years. 
The most frequent causes of death were renal insufficiency, 
stroke or myocardial infarction [3]. Starting from 2002 recom-
binant human a-galactosidese became available for enzymatic 
replacement therapy (ERT) of Fabry disease. Two formula-
tions are available: agalsidase a (Replagal, Shire, Cambrige, 
MA, USA) and agalsidase b (Fabrazyme, Genzyme, Boston 
MA, USA). Results of multi-center studies indicate that ERT 
in Fabry disease may be effective [4,5]. These studies mainly 
showed a decrease of globotriaosylceramide levels in endo-
thelial cells of the kidneys, heart and skin, accompanied by 
a stabilization of clinical symptoms and improvement in the 
quality of life [4,5].
In 1997, in our Department of Internal Medicine the di-
agnosis of Fabry disease was established in two adult males 
– brothers, at that time 38 and 36 years old. These patients 
 POLSKIE ARCHIWuM MEdYCYnY WEWnĘTRZnEJ 007; 7 (5-6)
CASE REPORTS
were already presented in detail in the previous issues of Polskie 
Archiwum Medycyny Wewnętrznej [6,7]. In May 2002 agalsidase 
b ERT was started in both cases. Early effects of such treat-
ment were described in the December 2004 issue [8]. The 
ERT was continued, and its results after four and a half years 
of such therapy are presented in this paper.
CASE PRESEnTATIOn
Fabry disease was diagnosed in two adult brothers (S.J. 
born in 1959 and A.J. born in 1961), based on a very low ac-
tivity of a-galactosidase A in blood leukocytes (that is 0.12 
nmol/mg per hour in S.J. and 0.2 nmol/mg in AJ; ref. value 
7.2 ±1.3). Mutation in the encoding region of enzyme was also 
identified (1235del115/insA).
Enzyme replacement therapy
Agalsidase b was infused intravenously (duration approx. 
5–7 h) every 2 weeks at a dose of 1 mg/kg of body weight. The 
older brother was also receiving a premedication (20-30 mg of 
metylprednisolone, i.v. and 1 g of acetaminphen) due to shivers 
and dyspnea during infusion.
The most significant clinical changes were observed in the 
first year of ERT. After that, the symptoms of Fabry disease 
stabilized. During the first year both brothers gained weight, 
and their temperature decreased to normal (tab.). S.J., but 
not A.J., reported the appearance of perspiration and better 
tolerance to heat. He noticed a distinct diminution of severe 
legs’ acroparaesthesia. Opposite to his older brother, A.J. com-
plained about initial deterioration of acroparaesthesia, which 
stabilized in the next few months. For several years before the 
initiation of ERT S.J. suffered from deep, narcotizing ulcer-
ations leading to the formation of abscesses which involved 
skin, subcutaneous tissue and penetrated to the metatarsal 
bones of both feet. In the first months of ERT quick healing of 
the present ulcers was observed [8]. In the next years abscess 
formation reappeared, albeit with low frequency, and healed 
rapidly after surgical drainage. In the 18th month of therapy 
necrosis of the head of the V left metatarsal bone and in the 
48th month necrosis of the head of the I right metatarsal bone 
required the surgical intervention with a partial bone amputa-
tion.
S.J. observed a distinct diminution of angina pectoris epi-
sodes during the first 6 months of ERT. Transthoracic echocar-
diography performed at the beginning of treatment revealed 
concentric, moderate hypertrophy of the left ventricle, together 
with the thickening of mitral and aortic leaflets and mild mi-
tral regurgitation. The adenosine test (140 μg/kg/min) showed 
a reduction in coronary blood flow in the left anterior descend-
ing artery. Recent echocardiography (January 2007) revealed 
similar left ventricular mass (240 g/m2 of body surface area by 
Penn convention vs. 242 in the year 2003), but remarkable fea-
tures of diastolic dysfunction with impaired relaxation (E/A = 
0.95; DT 228 msec; LVIVRT 127 msec; Ar 0.43 m/sec; E’/A’ 
0.59). Furthermore, in comparison to 2003 a partial fusion of 
the commissures of the aortic valve and the narrowing of the 
surface area to 1.8 cm2 (3.9 cm2 in 2003) were observed. After 
adenosine administration an improvement in coronary flow 
reserve was documented (2.4 vs 2.0 in 2003).
On the ECG lower voltage of QRS waves was noticed, but 
a possible regression of cardiac hypertrophy was not confirmed 
by echocardiography. 
Opposite to the older brother, the younger one did not 
complained about any angina symptoms. Transthoracic echo-
cardiography seemed to be unchanged, but because of the poor 
acoustic window a precise assessment was not possible. Like in 
the case of his older brother the ECG showed the decreased 
voltage of R and S waves. Additionally, the stable left boundle 
branch block (recurrent only in older ECGs) with a prolonga-
tion of PQ interval (0.1–0.12 s) was observed.
In both patients a moderate ventilatory impairment pre-
dominantly of the obstrucive type was observed by spirom-
etry, which was not influenced by ERT (tab.).
In S.J. at the beginning of ERT we observed a reduction 
of daily proteinuria (4.5 to 1.5) which remained stable in the 
next years. Creatinine clearance also remained stable (tab.). In 
A.J. initially low proteinuria increased slightly and then stabi-
lized (table). Serum creatinine concentration in both brothers 
increased, probably due to the higher body and muscle mass. 
In S.J. after 14 months of ERT the paraparesis of all fourth 
limbs developed, more distinct proximally and in legs on the 
left side [8]. Additionally, the impaired superficial feeling and 
the sense of vibration in distal parts of both feet were observed. 
Many focal demielinisation changes and some dystrophic cal-
cification in the nuclei of white matter (which were already 
present in 1999) were detected by MRI. Then all neurological 
symptoms diminished to the point where they did not disturb 
everyday activities. After 54 months of ERT S.J. reported a 
significant reduction in headaches and dizziness. Control MRI 
was similar to the one performed in 2003.
ERT was not effective for neurological manifestations in 
A.J. In the 5th month of treatment he was hospitalized for an 
ischemic stroke to the left hemisphere (confirmed by CT) with 
hemiparesis and speech impairment [8]. Fortunately, almost 
all clinical symptoms disappeared during the next 3 months. 
In MRI small ischaemic foci dispersed throughout the entire 
brain were observed. In the first months of treatment the pa-
tient also complained about vertigo, the feeling of a “noise in 
the ears” and body imbalance. All these symptoms were in-
terpreted as being of a vestibular origin [8]. In the next years 
neurological symptoms partially disappeared or stabilized. Re-
cently performed brain MRI did not show any new ischemic or 
demielinisation changes. 
A significant and rapid improvement in gastro-intestinal 
symptoms was noticed in both brothers. Abdominal pain, 
nausea and diarrhea appeared only occasionally and for a short 
time during these four and a half years.
In S.J. cataracts of both eyes developed due to the chronic 
steroid therapy started many years before the diagnosis of Fab-
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ry disease. He was operated on both eyes with sight restora-
tion. Already in 1999 abnormal blood vessels on the fundus 
of both eyes were observed (enlarged and braided). After four 
and a half years of ERT the picture remains unchanged.
No corneal degeneration, common to Fabry disease, was 
seen in the brothers.
A.J. eight years before the beginning of ERT lost the abil-
ity of hearing almost totally. Controlled audiogram performed 
in the 18th month of treatment confirmed a moderate hearing 
improvement. Recently audiogram shows the stable pattern of 
hearing.
In S.J. a mild, stable high frequency hearing impairment 
was observed.
Angiokeratomata in both subjects remain unchanged as 
concerns their number and localization. The picture of lymph-
edema of lower extremities is also stable.
dISCuSSIOn
We present clinical results of the long-term ERT using a-
galactosidase A (agalsidase b) in two adult brothers with Fabry 
disease. The treatment was started in late adulthood – at the 
ages of 43 and 45, respectively, and was continued for four and 
a half years. This is the longest observation of the effects of 
such treatment in Poland and one of the longest in the world. 
Up to now most of the published cases cover periods of about 
20–30 months. Generally, the results of ERT are worse for 
the older patients with chronic kidney disease than for the 
younger subjects [9]. However, ERT is nowadays considered 
the standard treatment for Fabry disease in all symptomatic 
cases [10]. At the beginning of our observation, both brothers 
were in the 5th decade of life and their disease was already in 
an advanced stage when the changes in the involved organs 
were most probably irreversible. Our observations confirm 
however that even if started so late ERT provides certain un-
questionable benefits. 
Cardiologic symptoms in Fabry disease are connected 
with: cardiac hyperthrophy, microvessels impairment and the 
pathologic function of heart conduction system (due to micro-
fibrosis). In both brothers during ERT we observed a decrease 
of the high QRS complex voltage. We could not confirm the 
regression of cardiac hyperthrophy by echocardiography (pro-
gression was also excluded). In summary, these results indi-
cated the stabilization of cardiac hypertrophy during four and 
Table. Clinical and laboratory symptoms of Fabry disease before and during ERT in patients S.J. and A.J. 













Body weight [kg] 62 68 78 69 74 80
Acroparaesthesia (in legs) ++++ ++++ +++ ++++ +++++ +++++
Angiokeratoma ++++ ++++ +++++ ++++ ++++ ++++
Headache +++++ ++++ +++ ++++ +++ +++
Dizziness +++ +++ ++ ++++ +++ +++
Angina ++++ – – – – –
Hypohidrosis +++++ +++ ++ +++++ +++++ +++++
Nausea +++ – – ++ – –
Diarrhea ++ + – ++ + +
Abdominal pain +++ + + + + –
Dyspnea +++++ ++++ +++ ++++ ++++ ++++
Proteinuria [g/d]  4.7   1.4   1.4  0.78  0.84   1.9
Creatinine clearance [ml/min] 48  49  56 95 98 100
Creatinine blood level [μmol/l] 88 120 128 75 81  92
Blood albumin level [g/l] 31  36  42 41 46  42
FEV1 % 68  57  65 50 50  46
Sokolov voltage index [mm] 61  50  36 68 50  44
P-Q [s]  0.12   0.12   0.12  0.08  0.1–0.12   0.1–0.12
EF % 60  55  60 65 61  60
Sokolov voltage index: R wave in V5 + S wave in V1. Subjective grading of symptoms from + to +++++. Abbreviations: EF – ejection 
fraction (in cardiac echocardiography), ERT – enzymatic replacement therapy, FEV1 – forced expiratory volume in 1 second, P-Q – P-Q interval
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a half years of ERT. In the older brother symptoms of angina 
pectoris quickly disappeared, associated with an improvement 
in coronary artery blood flow. As epicardial vessels of both 
brothers appeared normal on coronarography [6,8] the ob-
served beneficial effect of ERT was most probably related to 
the improvement in endothelial function in microcirculation. 
ERT was, however, unable to slow down the process of heart 
valve damage. The efficacy of ERT on cardio-vascular symp-
toms in Fabry disease was described in 2003 by Waldek [11] 
and Weidemann [12]. Recently a regression of heart hypertro-
phy and a decreased risk of myocardial infarction after ERT 
have been reported [5]. These beneficial effects are limited to 
some patients only. In ERT of Fabry disease the prognostic 
value of cardiac MRI has been suggested [13]. This diagnostic 
procedure was unavailable in our patients. 
The beneficial role of ERT for kidney function, most proba-
bly connected to the increased clearance of globotriasylcerami-
des from tissue, has been reported [14-17]. In our patients the 
stabilization of kidney function seemed especially important. 
In the period preceding ERT the increase of proteinuria and 
fast progression of renal insufficiency was already observed in 
the older brother. In his 6th decade of life the patient’s creati-
nine clearance is still around 50 ml/min.
By spirometry both brothers showed mixed ventilatory 
impairment, predominantly obstruction, with frequent symp-
toms of upper respiratory tract infection in the older one. ERT 
had no effect on spirometry values. This is in accordance with 
the available literature [18]. However, a woman with chronic 
respiratory failure due to Fabry disease and a distinct improve-
ment after ERT was recently described [19].
We are puzzled by a neurological deterioration observed in 
both brothers during the first months of treatment. Since new 
neurological complications as a result of ERT in Fabry disease 
have not been described, we tend to believe that they appeared 
in the natural course of the disease before ERT could have ex-
erted a beneficial effect. Stabilization of neurological status of 
our patients during the next years of ERT reinforces this point 
of view. The effect of ERT on the central nervous system is 
debatable. While some observed new degenerative changes in 
the brain white matter [20], others noticed the improvement 
of peripheral nerves conduction [21]. 
Finally, other effects related to the 54-month-ERT includ-
ed: total resolution of abdominal pain, chronic diarrhea and 
the improvement in the quality of life.
Unfortunately, we were not able to measure the level of 
sphingolipids and their possible clearance from tissues. How-
ever, it remains to be proven that there is a tight association 
between such clearance and the clinical response to the treat-
ment. We also could not exclude that in both bothers some 
beneficial effects were related to concomitant chronic treat-
ment, including ACE-ihibitors, statins and b-blockers. 
In summary, the four and a half year of ERT with agal-
sidase b shows beneficial effects on subjective and objective 
parameters of the disease in both brothers, especially the sta-
bilization of kidney function, cardiac hypertrophy, CNS ab-
normalities and as a result the improvement in the quality of 
life.
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